Targeting the pathobiology of neutrophil extracellular traps
Citryll – a dutch biotech company – is taking a new approach to treat autoimmune and other human diseases like lupus, vasculitis, pulmonary fibrosis, asthma, rheumatoid arthritis and organ damage due to sepsis, by targeting and inhibiting the source of auto-antigens and neutrophil extracellular trap (NET) derived toxic molecules instead of broadly targeting inflammation or acquired immunity.
Scientific Approach
Citryll targets Neutrophil Extracellular Traps (NET) formation with a human antibody CIT-013 that interferes with the formation of NETs as well as promotes the clearance of NETs. A range of human diseases with potential for SLE, RA, vasculitis, asthma, IPF and other indications can be treated with CIT-013.
CIT-013 Development
A first human dosing will be done in 2021 as part of a Single Ascending Dose (SAD) study in healthy volunteers. GMP production and formulation of the antibody is being carried out by Citryll’s CMC partner Lonza and CTA enabling studies are being finalised in 2020.
Latest News
Citryll Appoints Sjoerd van Gorp as Director of Operations
Sjoerd will work closely with key development partners to expand the therapeutic utilities of CIT-013, its clinical development candidate and derivatives.
Citryll Announces Dosing of the First Healthy Volunteer in a Phase 1 Clinical Trial for CIT-013, a First in Class Antagonist of NET Biology
Citryll today announced that the first healthy volunteer has been enrolled and dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of CIT-013.
Latest News
Citryll Appoints Sjoerd van Gorp as Director of Operations
Sjoerd will work closely with key development partners to expand the therapeutic utilities of CIT-013, its clinical development candidate and derivatives.
Citryll Announces Dosing of the First Healthy Volunteer in a Phase 1 Clinical Trial for CIT-013, a First in Class Antagonist of NET Biology
Citryll today announced that the first healthy volunteer has been enrolled and dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of CIT-013.
Citryll enters into bioanalytics partnership with Ardena for the clinical development of CIT-013, antagonist of NET biology and associated pathologies
Citryll’s first in class antibody drug candidate CIT-013 for autoimmune and chronic inflammatory diseases is beginning its bioanalytical phase at Ardena, a specialist pharmaceutical contract development and manufacturing organisation (CDMO).